EU/3/16/1770: Orphan designation for the treatment of adrenoleukodystrophy

5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride

Table of contents


On 18 November 2016, orphan designation (EU/3/16/1770) was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride (also known as MIN-102) for the treatment of adrenoleukodystrophy.

Key facts

Active substance
5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride
Intended use
Treatment of adrenoleukodystrophy
Orphan designation status
EU designation number
Date of designation

Minoryx Therapeutics S.L.
Permanent address of sponsor:Av. Ernest LLuch 32
08302 Mataró (Barcelona)
Tel. +34 93 702 19 75

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating